uploads///Graph

Ibrance: A Key Growth Driver for Pfizer

Margaret Patrick - Author
By

Nov. 5 2018, Updated 9:00 a.m. ET

Ibrance growth trends

According to Pfizer’s (PFE) third-quarter earnings conference call, its metastatic breast cancer drug, Ibrance, accounts for a little less than a 90% new-to-brand prescription volume share as of the end of the third quarter. With the first phase of its three-phase growth trajectory for the drug, Pfizer has managed to become a leading player in the CDK4/6 inhibitor class of drugs in a metastatic breast cancer indication.

Article continues below advertisement

As per Pfizer’s third-quarter earnings conference call, since the launch of Ibrance in the US market, it’s been actively involved in positioning the drug as the standard of care in the metastatic breast cancer setting. The company has estimated the total number of patients treated to date with Ibrance to be close to 90,000.

Performance in 2018

In the first nine months of 2018, Ibrance’s sales totaled $2.98 billion, a YoY rise of 24% on a reported basis and 23% on an operational basis. Of this revenue, the company earned $2.19 billion from the US market, a YoY rise of 6%. International markets contributed the remaining $807 million of the drug’s revenue.

In the third quarter, Pfizer reported global sales of $1.02 billion for Ibrance, a YoY rise of 17% on a reported basis and 18% on an operational basis. Of this revenue, the company earned $708 million from the US market, a YoY fall of 1%. International markets contributed the remaining $317 million of the drug’s revenue, a YoY rise of 93% on a reported basis and 98% on an operational basis.

As per the company’s third-quarter earnings conference call, international markets, including Japan and Europe, have emerged as major growth drivers for the company in 2018. In the third quarter, Ibrance witnessed sales worth $194 million from Western Europe, Finland, and Scandinavian countries, reflecting a YoY rise of 66% on a reported basis and 65% on an operational basis.

In the next article, we’ll discuss growth trends for Pfizer’s Xtandi in greater detail.

Advertisement

Latest Pfizer Inc News and Updates

    © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.